Choi Chang Hwan, Kim Tae Il, Kim Byung Chang, Shin Sung Jae, Lee Sang Kil, Kim Won Ho, Kim Hyon Suk
Department of Internal Medicine, Institute of Gastroenterology, Brain Korea 21 Project for Medical Science, Yonsei University College of Medicine, Seoul, Korea.
Dis Colon Rectum. 2006 Dec;49(12):1849-59. doi: 10.1007/s10350-006-0706-z.
This study was designed to assess anti-Saccharomyces cerevisiae antibody positive rate in Behçet's disease and intestinal Behçet's disease and to evaluate whether anti-Saccharomyces cerevisiae antibody expression is associated with clinical findings at diagnosis and clinical course of intestinal Behçet's disease.
One hundred six patients with intestinal Behçet's disease, 30 patients with Behçet's disease, and 45 healthy control subjects were included. Anti-Saccharomyces cerevisiae antibody was detected by indirect immunofluorescence assay. According to anti-Saccharomyces cerevisiae antibody expression, the various parameters at diagnosis, cumulative relapse rates, and cumulative probabilities of operation were analyzed.
Anti-Saccharomyces cerevisiae antibody positive rate was 44.3 percent in intestinal Behçet's disease, 3.3 percent in Behçet's disease, and 8.8 percent in healthy control subjects. In patients with intestinal Behçet's disease, age, gender, distribution of Behçet's disease subtype, symptoms, laboratory tests, and colonoscopic findings at diagnosis were not different according to anti-Saccharomyces cerevisiae antibody expression. Cumulative probability of a first operation was significantly higher in anti-Saccharomyces cerevisiae antibody (+) intestinal Behçet's disease than in anti-Saccharomyces cerevisiae antibody (-) intestinal Behçet's disease: 44.8 and 17.2 percent at one year, and 53 and 24.3 percent at two years after diagnosis, respectively (P=0.006). The number of patients who underwent two or more operations was higher in anti-Saccharomyces cerevisiae antibody (+) intestinal Behçet's disease than in anti-Saccharomyces cerevisiae antibody (-) intestinal Behçet's disease (21.3 vs. 8.5 percent). The cumulative relapse rates were not different between the two groups.
Anti-Saccharomyces cerevisiae antibody positive rate was 44.3 percent in intestinal Behçet's disease. Clinical findings at diagnosis and cumulative relapse rates of intestinal Behçet's disease were not found to be associated with anti-Saccharomyces cerevisiae antibody expression. However, patients with anti-Saccharomyces cerevisiae antibody (+) intestinal Behçet's disease were more likely to receive surgical treatment.
本研究旨在评估白塞病及肠道白塞病中抗酿酒酵母抗体阳性率,并评价抗酿酒酵母抗体表达是否与肠道白塞病诊断时的临床特征及临床病程相关。
纳入106例肠道白塞病患者、30例白塞病患者及45例健康对照者。采用间接免疫荧光法检测抗酿酒酵母抗体。根据抗酿酒酵母抗体表达情况,分析诊断时的各项参数、累积复发率及手术累积概率。
肠道白塞病患者抗酿酒酵母抗体阳性率为44.3%,白塞病患者为3.3%,健康对照者为8.8%。在肠道白塞病患者中,根据抗酿酒酵母抗体表达情况,诊断时的年龄、性别、白塞病亚型分布、症状、实验室检查及结肠镜检查结果并无差异。抗酿酒酵母抗体(+)的肠道白塞病患者首次手术的累积概率显著高于抗酿酒酵母抗体(-)的肠道白塞病患者:诊断后1年分别为44.8%和17.2%,2年分别为53%和24.3%(P=0.006)。抗酿酒酵母抗体(+)的肠道白塞病患者接受两次或更多次手术的人数高于抗酿酒酵母抗体(-)的肠道白塞病患者(21.3%对8.5%)。两组的累积复发率无差异。
肠道白塞病患者抗酿酒酵母抗体阳性率为44.3%。未发现肠道白塞病诊断时的临床特征及累积复发率与抗酿酒酵母抗体表达相关。然而,抗酿酒酵母抗体(+)的肠道白塞病患者更有可能接受手术治疗。